



neurinnov
INNOVATION IN NEUROSTIMULATION


Redefining the Standards of Neurostimulation




Nicolas SERANDOUR
CEO
nicolas.serandour@neurinnov.com




Unlocking the potential of neurostimulation





Expanding the horizon of neurostimulation




The challenges of precision in neurostimulation



Our breakthrough technology




ASIC and electrodes – the core of our technology





Source: Tigra et al. Journal of NeuroEngineering and Rehabilitation, 2020

Restoring hand functions – Why our first indication?



Solution designed with patients and physicians in mind



Neurostimulation for functional movements validated



Proven feasibility

- Study design:
 - 9 patients
 - 1-hour implantation
- Synergistic recruitment of muscle fibers
- Wide diversity of movements achieved
- Selective electrical stimulation validated

1st clinical application

- Study design:
 - 4 patients
 - **Fully** implanted device
- First step ahead of the pivotal study (30 patients)

Demonstrated performance

- Study design:
 - 4 patients
 - **Partially** implanted (electrodes only)
- Implantation for 28 days
- Restoration of functional hand movements
- Effectiveness and reliability
- Proven feasibility of electrodes in chronic use



Dynamic IP strategy as a driver of Neurinnov's value



- **Neurinnov is a first-mover in selective neurostimulation with**

- seven patent families
- trade secrets
- and deep academic collaborations

- **Initial filings in France, extended via PCT to Europe, USA, Canada, China, and Australia**

- **Selective stimulation** → Accurate 3D power distribution across multipolar electrodes
- **Reliable and accurate stimulation** → Anodic vs. cathodic accurate matching of amplitude & dynamics for high precision stimulation and active charge balance
- **Decentralised intelligence** → Digital architecture for optimised neurostimulation
- **Configuration software & training** → Advanced configuration software enhancing usability and adaptability
- **Communication bus** → Safe and deterministic transmission link
- **Inductive transcutaneous link** → Wireless energy transfer for seamless operation
- **Fast stimulation sequencing** → Optimising synergistic effects of neurostimulation



Team leaders



Nicolas Sérandour, CEO
Investment Bank and senior roles in medtech companies



David Andreu, co-founder, CTO & General Manager
HDR PhD in Industrial Informatics




David Guiraud, co-founder & CSO
HDR PhD of Biomedical Engineering



Scientific and technical advisors

- **Christine Azevedo Coste**, INRIA Research Director
- **Cédric Briand**, MSEE, MBA, 20 years of experience in Cochlear Implants and Neurostimulation as CEO (Neurelec) and GM (Oticon Medical, Cochlear)
- **Charles Fattal**, PhD, MD Physical and Rehabilitation Medicine, USSAP, France
- **Jacques Teissier**, orthopaedic and trauma surgeon, Saint-Jean Clinic, Montpellier, France

Development roadmap



Why investing in Neurinnov?



1

Highly differentiated selective neurostimulation platform unlocking new medical applications

2

First indication enables a fast-track regulatory pathway, addressing critical unmet needs

3

Human proof of concept achieved, significantly de-risking the technology

4

Growing IP portfolio securing 15+ years of R&D, ensuring technological leadership

5

World-class team leading the field in selective neurostimulation, supported by EU and renown KOLs

6

Breakthrough near clinical validation with minimal dilution

Disclaimer



- The information contained in this document (“Presentation”) has been prepared by Neurinnov SAS (the “Company”). It has not been fully verified and is subject to material updating, revision and further amendment. This Presentation may contain forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These forward-looking statements speak only as of the date of this Presentation and the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Presentation.
- Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.
- This Presentation should not be considered as the giving of investment advice by the Company, or any of their respective shareholders, directors, officers, agents, employees or advisers. In particular, this Presentation does not constitute an offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
- While the information contained herein has been prepared in good faith, none of the Company, nor any its respective shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as “Information”) and liability therefore is expressly disclaimed. Accordingly, none of the Company, nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.



1st prize
(2012)

Prix académique des
sciences (2010)



CAP GAMMA - ZAC EUROMEDECINE II
1682 rue de la Valsière
34790 Grabels - France
www.neurinnov.com



Bronze medal
(2005)



Innovation Prize of i-site
(2019)